6576. Nitrendipine

Nomenclature

CAS number: 39562-70-4
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester; ethyl 1,4-dihydro-5-(acetoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate; 3-ethyl-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; Bay e 5009; Bayotensin (Bayer); Baypress (Bayer); Bylotensin (Yoshitomi); Deiten (ABC); Nidrel (Specia).
C18H20N2O6; mol wt 360.36.
C 59.99%, H 5.59%, N 7.77%, O 26.64%.

Description and references

Dihydropyridine calcium channel blocker. Prepn: H. Meyer et al., DE 2117571; eidem, US 3799934 (1972, 1974 both to Bayer); eidem, Arzneim.-Forsch. 31, 407 (1981). Series of articles on pharmacology: ibid. 2056-2067. Hemodynamic effects: H. O. Ventura et al., Am. J. Cardiol. 51, 783 (1983). Pharmacokinetics: L. Hansson et al., Hypertension 5, Suppl. II, II-25 (1983). HPLC determn in human serum: R. A. Janis et al., J. Clin. Pharmacol. 23, 266 (1983). Double-blind, controlled clinical trial: U. Brugmann et al., Herz 10, 53 (1985). Symposium on pharmacology and clinical efficacy: J. Cardiovasc. Pharmacol. 6 Suppl. 7, S929-S1113 (1984). Toxicology studies: K. Hoffmann, “Toxicological Studies with Nitrendipine” in Nitrendipine, A. Scriabine et al., Eds. (Urban & Schwarzenberg, Baltimore, 1984) pp 25-32. Review: A. Scriabine et al., “Nitrendipine” in New Drugs Annual: Cardiovascular Drugs Vol. 2, A. Scriabine, Ed. (Raven Press, New York, 1984) pp 37-49.

Chemical structure

Properties

Crystals from ethanol, mp 158°. Relatively insol in water. LD50 in mice, rats (mg/kg): 39, 12.6 i.v.; 2540, >10000 orally (Hoffmann).

Therapeutic Category

Antihypertensive.

Keywords

Antihypertensive; Dihydropyridine Derivatives; Calcium Channel Blocker; Dihydropyridine Derivatives